Contemporary methodological issues in drug development: the functionality of blinding is poorly studied

Area of Science:

• Drug development
• Clinical trial methodology
• Biostatistics

Background:

• Blinding is a key principle in randomized clinical trials (RCTs) for minimizing bias.
• The effectiveness and functionality of blinding techniques are not well understood or studied.
• The 'blinding' domain of risk of bias is often assumed to be low-risk in blinded RCTs.

Purpose of the Study:

• To review the functionality of blinding in bias minimization structures within RCTs.
• To highlight the need for further empirical investigation into blinding techniques.
• To challenge the automatic assumption of low risk of bias based solely on trial blinding.

Main Methods:

• Literature review of blinding in drug development and clinical trials.
• Analysis of the role of blinding in the context of bias minimization.
• Examination of empirical evidence regarding the effectiveness of blinding.

Main Results:

• Blinding's functionality in preventing bias is not consistently assured.
• The assumption of low risk of bias in blinded trials is not always supported by evidence.
• There is a significant gap in empirical research on blinding effectiveness.

Conclusions:

• The effectiveness of blinding in drug development requires further rigorous study.
• Relying solely on the label 'blinded' for RCTs may oversimplify risk of bias assessment.
• Further research is essential to understand and optimize blinding techniques for robust clinical trial outcomes.